BI 1291583 is an experimental medication being tested for its safety and effectiveness in treating patients with bronchiectasis. Bronchiectasis is a lung condition where the airways become widened and scarred, leading to mucus build-up and frequent lung infections. This medication is taken orally, which means it is swallowed in the form of a pill or liquid. The goal of using BI 1291583 in this trial is to see if it can help reduce symptoms and improve lung function in people with this condition. The study is also focused on monitoring any side effects that patients might experience while taking this medication over a long period. This helps researchers understand how safe the medication is for long-term use.

Bronchiectasis – Bronchiectasis is a chronic condition where the walls of the bronchi, the large air passages from the trachea to the lungs, become permanently widened. This widening is often due to inflammation and infection, leading to a cycle of damage and further infection. As the disease progresses, the airways lose their ability to clear out mucus, resulting in frequent lung infections and blockages. Patients often experience a persistent cough, production of large amounts of sputum, and shortness of breath. Over time, the repeated infections and inflammation can cause further damage to the lung tissue. The condition can lead to a decline in lung function and increased respiratory symptoms.